Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

May 31, 2020

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Docetaxel

5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation

DRUG

Nedaplatin

5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation

RADIATION

chest radiation

continuous chest radiation at 64 Gy/32f

Trial Locations (1)

510060

Hui Liu, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02964455 - Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter